Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro for $43.00 per share in cash without interest.
The specialty pharmacy business could be valued at more than $4 billion in a sale, per a Bloomberg report, which cited people familiar with the matter.
Labor challenges, the expansion of healthcare services, store-count rationalization and PBM reform are among the front-burner issues in the year ahead.
The application process is open to diverse-owned suppliers, which include small and mid-size businesses that are at least 5% owned, controlled and operated by minorities, veterans or people with disabilities.
